The mean duration of growth hormone pre-treatment for all remaining patients (10.2 %) was similar for all indications (27.8 ± 19.2 months), with the exception of one patient with PWS whose pre-treatment period was 47.3 months. This evidence concerns the gene GH1 and Prader-Willi syndrome.